RCAL
ABBV icon

Rose Capital Advisors LLC’s AbbVie ABBV Stock Holding History

Rose Capital Advisors LLC’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$266K Buy
+1,056
New +$227K 0.13% 90

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return

Rose Capital Advisors LLC's ABBV Position: Q2 2026 in Review

Rose Capital Advisors LLC opened a new position in AbbVie (ABBV) in Q2 2026: 1,056 shares worth $266K. The stake represents 0.13% of the portfolio and ranks #90 among its holdings.

2,841 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Rose Capital Advisors LLC held 1,056 shares of AbbVie worth $266K as of Q2 2026.
  • AbbVie was a new Rose Capital Advisors LLC position in Q2 2026.
  • AbbVie made up 0.13% of Rose Capital Advisors LLC's portfolio in Q2 2026, its #90 holding.
  • 2,841 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Rose Capital Advisors LLC's 13F filing for Q2 2026, filed 7 Aug 2026.